---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000121"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:44:47.355859+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials

## Summary
- Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.
- Net loss $3.4M vs $5.8M in Q3 2023; decrease due to -$1.1M non-cash change in contingent consideration.
- R&D expenses net $1.3M after $0.9M Théa reimbursement; G&A flat at $1.4M.
- IND approved for ABACUS-2 Phase 2 study of KIO-301 in retinitis pigmentosa; first patient dosing in 2025.
- Phase 2 KLARITY trial of KIO-104 designed; submission for approval on track for Q4 2024.

## SEC filing metadata
- accession: 0001372514-24-000121
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000121/0001372514-24-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000121/kprx-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000121
- JSON: https://secwatch.observer/filing/0001372514-24-000121.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.